Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Achilles Therapeutics ( (ACHL) ).
Achilles Therapeutics announced the resignation of three members from its Board of Directors, effective December 31, 2024, as part of a planned reduction in board size. The resignations of Julie O’Neill, Michael Giordano, and Bernhard Ehmer are not due to any disagreements with the company’s operations or policies, suggesting a strategic realignment rather than internal conflict.
More about Achilles Therapeutics
Achilles Therapeutics is a biotechnology company based in the United Kingdom. The company focuses on developing precision T cell therapies targeting clonal neoantigens for the treatment of cancer.
YTD Price Performance: 1.67%
Average Trading Volume: 163,894
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $47.66M
See more data about ACHL stock on TipRanks’ Stock Analysis page.